The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease Chronic Pain.
CompletedNot applicableNCT07066072
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this clinical trial study is to assess effect of radiofrequency on chronic pain of sickle cell disease pain . All SCA participants who fulfilled inclusion and exclusion criteria were 220; only 170 participant agreed to consent for the study . Participants who seek frequent medical attention were included in the TECAR group without randomization and they were 15 patients, and the rest of the participants (155 patient) were randomized according to the following ratio as 1:1.2 respectively for both arms arm1: the TECAR group arm 2: the control group . The main questions to answer are: primary outcome measure: assess short term effect of TECAR therapy on chronic sickle cell diaease chronic pain by assessment of change in pain scores following 1st TECAR session. secondary outcomes: assess long term effect of TECAR therapy by assessment of change in chronic pain scores along overall period of study (6weeks). TECAR (Capacitive and Resistive Energy Transfer device) used: (C-200 Capenergy Spain) participants: 2 arms : one arm: TECAR group. 2nd arm: control group. one arm: received TECAR therapy in addition to the standard of care for SCA (hydroxyurea, analgesics \[NSAIDs or paracetamol\], and blood transfusion on demand). The second arm received standard of care only. tools used to assess pain: 1. VAS questionnaire. 2. BPI questionnaire. 3. HRQOL questionnaire.
Study details
- Official title
- The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain
- Conditions
- the Use of Radiofrequency Ablation in Form of TECAR(Capacitive and Resistive Transfer Energy) in Chronic Pain of Sickle Cell Disease Patients
- Interventions
- Device: Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer).
- Other: standard pharmacological therapy in sickle cell disease like hydroxyurea,paracetamol,ibubrofen and blood transfusion if needed
- Sponsor
- Cairo University
- Start date
- 2022-12-01
- Primary completion
- 2025-01-01
- Sex
- All
- Age range
- from 6 Years to 30 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. All types of sickle cell disease (SS/SB0/SB+/SS trait) 2. Age of patients ranging from 6 years to 30 years. 3. SCA patients with known and unknown cause of chronic pain Exclusion Criteria: 1. Those patients with associated chronic disease or end organ damage. 2. patients in acute Vaso occlusive crisis. 3. Patients on antiepileptics or antidepressant drugs.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07066072